Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood (2020) Vol. 135, Iss. 24, pp. 2137-2145
Open Access | Times Cited: 601

Showing 1-25 of 601 citing articles:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1738
Acute myeloid leukemia: current progress and future directions
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 528
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 45-64
Closed Access | Times Cited: 255
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 502-526
Open Access | Times Cited: 219
Towards precision medicine for AML
Hartmut Döhner, Andrew H. Wei, Bob Löwenberg
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 577-590
Closed Access | Times Cited: 208
Emerging agents and regimens for AML
Hongtao Liu
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 183
Acute myeloid leukaemia
Courtney D. DiNardo, Harry P. Erba, Sylvie D. Freeman, et al.
The Lancet (2023) Vol. 401, Iss. 10393, pp. 2073-2086
Open Access | Times Cited: 173
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, et al.
Cancer (2021) Vol. 127, Iss. 12, pp. 2049-2061
Open Access | Times Cited: 172
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 164
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chong Chyn Chua, Andrew W. Roberts, John Reynolds, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 30, pp. 3506-3517
Closed Access | Times Cited: 152
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 142
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E. Perl, Joseph Maly, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 35, pp. 4048-4059
Open Access | Times Cited: 138
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Cancer (2021) Vol. 127, Iss. 8, pp. 1186-1207
Open Access | Times Cited: 125
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 8, pp. e552-e561
Open Access | Times Cited: 125
Updates on targeted therapies for acute myeloid leukaemia
Sabine Käyser, Mark J. Levis
British Journal of Haematology (2021) Vol. 196, Iss. 2, pp. 316-328
Open Access | Times Cited: 124
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
Recent advances in targeted therapies in acute myeloid leukemia
Rahul S. Bhansali, Keith W. Pratz, Catherine Lai
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 119
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
Eunice S. Wang, Pau Montesinos, Mark D. Minden, et al.
Blood (2022) Vol. 140, Iss. 17, pp. 1845-1857
Open Access | Times Cited: 87
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
CD47–SIRPα-targeted therapeutics: status and prospects
Roy L. Maute, Jianqing Xu, I L Weissman
Immuno-Oncology Technology (2022) Vol. 13, pp. 100070-100070
Open Access | Times Cited: 80
The clinical impact of the molecular landscape of acute myeloid leukemia
Sabine Käyser, Mark J. Levis
Haematologica (2023) Vol. 108, Iss. 2, pp. 308-320
Open Access | Times Cited: 73
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Tapan M. Kadia, Patrick K. Reville, Xuemei Wang, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 33, pp. 3848-3857
Open Access | Times Cited: 70
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 41
Targeting apoptotic pathways for cancer therapy
Xiaobing Tian, Praveen R. Srinivasan, Vida Tajiknia, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 22
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top